Dr. Shah on the Safety of a Novel Dual-Targeted CAR T-Cell Therapy in Non-Hodgkin Lymphoma
January 14th 2021
Nirav Shah, MD, MCW, discusses the safety profile of an anti-CD20/anti-CD19 CAR T-cell therapy under investigation in the treatment of patients with non-Hodgkin lymphoma.